<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34629206</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>41 Suppl 1</Volume><PubDate><Year>2023</Year><Month>Apr</Month><Day>06</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic.</ArticleTitle><Pagination><StartPage>A93</StartPage><EndPage>A104</EndPage><MedlinePgn>A93-A104</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2021.09.037</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(21)01228-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Since July 2019, Pakistan and Afghanistan have been facing an outbreak of serotype-2 circulating vaccine derived poliovirus (cVDPV2) in addition to continued transmission of serotype-1 wild poliovirus (WPV1) and SARS-CoV-2 in 2020. Understanding the risks of cVDPV2 transmission due to pause of global vaccination efforts and the impact of potential vaccination response strategies in the current context of COVID-19 mitigation measures is critical.</AbstractText><AbstractText Label="METHODS">We developed a stochastic, geographically structured mathematical model of cVDPV2 transmission which captures both mucosal and humoral immunity separately and allows for reversion of serotype-2 oral polio vaccine (OPV2) virus to cVDPV2 following vaccine administration. The model includes geographic heterogeneities in vaccination coverage, population immunity and population movement. The model was fitted to historic cVDPV2 cases in Pakistan and Afghanistan between January 2010-April 2016 and July 2019-March 2020 using iterated particle filtering. The model was used to simulate spread of cVDPV2 infection from July 2019 to explore impact of various proposed vaccination responses on stopping transmission and risk of spread of reverted Sabin-2 under varying assumptions of impacts from COVID-19 lockdown measures on movement patterns as well as declines in vaccination coverage.</AbstractText><AbstractText Label="RESULTS">Simulated monthly incidence of cVDPV2 from the best-fit model demonstrated general spatio-temporal alignment with observed cVDPV2 cases. The model predicted substantial spread of cVDPV2 infection, with widespread transmission through 2020 in the absence of any vaccination activities. Vaccination responses were predicted to substantially reduce transmission and case burden, with a greater impact from earlier responses and those with larger geographic scope. While the greatest risk of seeding reverted Sabin-2 was predicted in areas targeted with OPV2, subsequent spread was greatest in areas with no or delayed response. The proposed vaccination strategy demonstrated ability to stop the cVDPV2 outbreak (with low risk of reverted Sabin-2 spread) by February 2021.</AbstractText><AbstractText Label="CONCLUSION">Outbreak response vaccination campaigns against cVDPV2 will be challenging throughout the COVID-19 pandemic but must be implemented urgently when feasible to stop transmission of cVDPV2.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Molodecky</LastName><ForeName>Natalia A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, UK; World Health Organization (WHO), Islamabad, Pakistan; National Emergency Operations Centre for Polio Eradication, Islamabad, Pakistan; World Health Organization (WHO), Geneva, Switzerland. Electronic address: n.molodecky@imperial.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafari</LastName><ForeName>Hamid</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>World Health Organization (WHO), EMRO, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safdar</LastName><ForeName>Rana M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>National Emergency Operations Centre for Polio Eradication, Islamabad, Pakistan; Ministry of National Health Services, Regulations and Coordination, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Jamal A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>World Health Organization (WHO), Islamabad, Pakistan; National Emergency Operations Centre for Polio Eradication, Islamabad, Pakistan; World Health Organization (WHO), Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahamud</LastName><ForeName>Abdirahman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>World Health Organization (WHO), Islamabad, Pakistan; National Emergency Operations Centre for Polio Eradication, Islamabad, Pakistan; World Health Organization (WHO), Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandyopadhyay</LastName><ForeName>Ananda S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Bill &amp; Melinda Gates Foundation, Seattle, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shukla</LastName><ForeName>Hemant</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>World Health Organization (WHO), EMRO, Amman, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quddus</LastName><ForeName>Arshad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>World Health Organization (WHO), Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaffran</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>World Health Organization (WHO), Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutter</LastName><ForeName>Roland W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>World Health Organization (WHO), Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassly</LastName><ForeName>Nicholas C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blake</LastName><ForeName>Isobel M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant><Grant><GrantID>MR/R015600/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000346" MajorTopicYN="N" Type="Geographic">Afghanistan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010154" MajorTopicYN="N" Type="Geographic">Pakistan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>11</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34629206</ArticleId><ArticleId IdType="pmc">PMC8463303</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2021.09.037</ArticleId><ArticleId IdType="pii">S0264-410X(21)01228-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GPEI. Call to action to support COVID-19 response. Polio Oversight Board Statement. Available at: http://polioeradication.org/news-post/call-to-action-to-support-covid-19-response/.</Citation></Reference><Reference><Citation>GPEI. Circulating vaccine-derived poliovirus. Available at: http://polioeradication.org/polio-today/polio-now/this-week/circulating-vaccine-derived-poliovirus/.</Citation></Reference><Reference><Citation>Macklin G.R., O&#x2019;Reilly K.M., Grassly N.C., Edmunds W.J., Mach O., Santhana Gopala Krishnan R., et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020;368(6489):401&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>L. V. Cooper et al., Risk factors for spread of vaccine-derived type 2 polioviruses in Africa following global withdrawal of trivalent oral poliovirus vaccine and impact of outbreak response with monovalent vaccine: a retrospective analysis of surveillance data. Lancet Infectious Diseases (in press).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8799632</ArticleId><ArticleId IdType="pubmed">34648733</ArticleId></ArticleIdList></Reference><Reference><Citation>GPEI. SOPs Responding to a poliovirus event of outbreak. March 2020. Available at: https://polioeradication.org/wp-content/uploads/2020/04/POL-SOP-V3.1-20200424.pdf.</Citation></Reference><Reference><Citation>Ahmadi A., Essar M.Y., Lin X., Adebisi Y.A., Lucero-Prisno D.E. Polio in Afghanistan: The Current Situation amid COVID-19. Am J Trop Med Hyg. 2020;103:1367&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543832</ArticleId><ArticleId IdType="pubmed">32861265</ArticleId></ArticleIdList></Reference><Reference><Citation>S. Ahmad et al., Polio Amidst COVID-19 in Pakistan: What are the Efforts Being Made and Challenges at Hand? Am J Trop Med Hyg 104, 446-448 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7866369</ArticleId><ArticleId IdType="pubmed">33269673</ArticleId></ArticleIdList></Reference><Reference><Citation>Din M., Ali H., Khan M., Waris A., Ullah S., Kashif M., et al. Impact of COVID-19 on polio vaccination in Pakistan: a concise overview. Rev Med Virol. 2021;31(4) https://10.1002/rmv.v31.410.1002/rmv.2190.</Citation><ArticleIdList><ArticleId IdType="pubmed">33176028</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Essential polio vaccination campaigns resume after strict COVID-19 prevention measures. Available at: http://www.emro.who.int/fr/polio/polio-news/essential-polio-vaccination-campaigns-resume-under-strict-covid-19-prevention-measures.html.</Citation></Reference><Reference><Citation>Afghanistan National Emergency Action Plan for Polio Eradication. 2021. Available at: https://polioeradication.org/wp-content/uploads/2021/05/Afghanistan_NEAP_2021.pdf.</Citation></Reference><Reference><Citation>Molodecky N.A., et al. Risk factors and short-term projections for serotype-1 poliomyelitis incidence in Pakistan: A spatiotemporal analysis. PLoS Med. 2017;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5467805</ArticleId><ArticleId IdType="pubmed">28604777</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Salort M., et al. Population Immunity against Serotype-2 Poliomyelitis Leading up to the Global Withdrawal of the Oral Poliovirus Vaccine: Spatio-temporal Modelling of Surveillance Data. PLoS Med. 2016;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5049753</ArticleId><ArticleId IdType="pubmed">27701425</ArticleId></ArticleIdList></Reference><Reference><Citation>Laboratory surveillance for wild and vaccine-derived polioviruses--worldwide, January 2007-June 2008. MMWR. Morbidity and mortality weekly report 57, 967-970 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18772852</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner B.G., Behrend M.R., Klein D.J., Upfill-Brown A.M., Eckhoff P.A., Hu H., et al. Quantifying the impact of expanded age group campaigns for polio eradication. PLoS ONE. 2014;9(12):e113538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4249973</ArticleId><ArticleId IdType="pubmed">25437014</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly N.C., Fraser C., Wenger J., Deshpande J.M., Sutter R.W., Heymann D.L., et al. New strategies for the elimination of polio from India. Science. 2006;314(5802):1150&#x2013;1153.</Citation><ArticleIdList><ArticleId IdType="pubmed">17110580</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake I.M., Martin R., Goel A., Khetsuriani N., Everts J., Wolff C., et al. The role of older children and adults in wild poliovirus transmission. Proc Natl Acad Sci USA. 2014;111(29):10604&#x2013;10609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115498</ArticleId><ArticleId IdType="pubmed">25002465</ArticleId></ArticleIdList></Reference><Reference><Citation>Simini F., Gonz&#xe1;lez M.C., Maritan A., Barab&#xe1;si A.-L. A universal model for mobility and migration patterns. Nature. 2012;484(7392):96&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">22367540</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib M.A., et al. Community engagement and integrated health and polio immunisation campaigns in conflict-affected areas of Pakistan: a cluster randomised controlled trial. The Lancet. Global health. 2017;5:e593&#x2013;e603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5439031</ArticleId><ArticleId IdType="pubmed">28495264</ArticleId></ArticleIdList></Reference><Reference><Citation>Melnick J.L., Ledinko N. Development of neutralizing antibodies against the three types of poliomyelitis virus during an epidemic period; the ratio of inapparent infection to clinical poliomyelitis. Am J Hyg. 1953;58:207&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">13080261</ArticleId></ArticleIdList></Reference><Reference><Citation>Penttinen K., Patiala R. The paralytic/infected ratio in a susceptible population during a polio type I epidemic. Ann Med Exp Biol Fenn. 1961;39:195&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">14038262</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathanson N., Kew O.M. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010;172(11):1213&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2991634</ArticleId><ArticleId IdType="pubmed">20978089</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelfand H.M., Leblanc D.R., Fox J.P., Conwell D.P. Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. Am J Hyg. 1957;65:367&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">13424522</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Salort M., Burns C.C., Lyons H., Blake I.M., Jafari H., Oberste M.S., et al. Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame. PLoS Pathog. 2016;12(7):e1005728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4934862</ArticleId><ArticleId IdType="pubmed">27384947</ArticleId></ArticleIdList></Reference><Reference><Citation>Wringe A., Fine P.E.M., Sutter R.W., Kew O.M., Esparza J. Estimating the extent of vaccine-derived poliovirus infection. PLoS ONE. 2008;3(10):e3433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570794</ArticleId><ArticleId IdType="pubmed">18958288</ArticleId></ArticleIdList></Reference><Reference><Citation>N. C. Grassly et al., Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. The Journal of infectious diseases 205, 1554-1561 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22448007</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderEnde K., Voorman A., Khan S., Anand A., Snider C.J., Goel A., et al. New analytic approaches for analyzing and presenting polio surveillance data to supplement standard performance indicators. Vaccine X. 2020;4:100059. doi: 10.1016/j.jvacx.2020.100059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvacx.2020.100059</ArticleId><ArticleId IdType="pmc">PMC7090369</ArticleId><ArticleId IdType="pubmed">32215368</ArticleId></ArticleIdList></Reference><Reference><Citation>King A., Nguyen D., Ionides E. Statistical Inference for Partially Observed Markov Processes via the R Package pomp. J Stat Softw. 2016;69:1&#x2013;43.</Citation></Reference><Reference><Citation>Google. COVID-19 Community Mobility Reports. Available at: https://www.google.com/covid19/mobility/.</Citation></Reference><Reference><Citation>S. Chandir, D. A. Siddiqi, H. Setayesh, A. J. Khan, Impact of COVID-19 lockdown on routine immunisation in Karachi, Pakistan. The Lancet. Global health, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7324087</ArticleId><ArticleId IdType="pubmed">32615076</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesolowski A., Qureshi T., Boni M.F., Sunds&#xf8;y P.R., Johansson M.A., Rasheed S.B., et al. Impact of human mobility on the emergence of dengue epidemics in Pakistan. Proc Natl Acad Sci USA. 2015;112(38):11887&#x2013;11892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586847</ArticleId><ArticleId IdType="pubmed">26351662</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., De Coster I., Bandyopadhyay A.S., Revets H., Withanage K., De Smedt P., et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet (London, England) 2019;394(10193):148&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>GPEI. nOPV2 Frequently Asked Questions. July 2020. Available at: http://polioeradication.org/wp-content/uploads/2020/07/nOPV2-FAQs-REVISED-202007.pdf.</Citation></Reference><Reference><Citation>Stern A., Yeh M.T., Zinger T., Smith M., Wright C., Ling G., et al. The Evolutionary Pathway to Virulence of an RNA Virus. Cell. 2017;169(1):35&#x2013;46.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5787669</ArticleId><ArticleId IdType="pubmed">28340348</ArticleId></ArticleIdList></Reference><Reference><Citation>Famulare M., Selinger C., McCarthy K.A., Eckhoff P.A., Chabot-Couture G. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine. PLoS Biol. 2018;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942853</ArticleId><ArticleId IdType="pubmed">29702638</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakistan Bureau of Statistics. Government of Pakistan. Pakistan Social and Living Standards Measurement Survey 2018-19. Available at: http://www.pbs.gov.pk/content/pakistan-social-and-living-standards-measurement.</Citation></Reference><Reference><Citation>Sutter R.W., John T.J., Jain H., Agarkhedkar S., Ramanan P.V., Verma H., et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet (London, England) 2010;376(9753):1682&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pubmed">20980048</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake I.M., Chenoweth P., Okayasu H., Donnelly C.A., Aylward R.B., Grassly N.C. Faster Detection of Poliomyelitis Outbreaks to Support Polio Eradication. Emerg Infect Dis. 2016;22(3):449&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766913</ArticleId><ArticleId IdType="pubmed">26890053</ArticleId></ArticleIdList></Reference><Reference><Citation>GPEI. Polio eradication in the context of the COVID-19 pandemic. Updated urgent country and regional recommendations. Available at: http://polioeradication.org/wp-content/uploads/2020/03/updated-POB-country-and-regional-recommendations-20200526.pdf.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>